Sirtuin 6 (SIRT6) is associated with longevity and is also a tumor suppressor. Identification of molecular regulators of SIRT6 might enable its activation therapeutically in cancer patients. In various breast cancer cell lines, we found that SIRT6 was phosphorylated at Ser 338 by the kinase AKT1, which induced the interaction and ubiquitination of SIRT6 by MDM2, targeting SIRT6 for protease-dependent degradation. The survival of breast cancer patients positively correlated with the abundance of SIRT6 and inversely correlated with the phosphorylation of SIRT6 at Ser 338 . In a panel of breast tumor biopsies, SIRT6 abundance inversely correlated with the abundance of phosphorylated AKT. Inhibiting AKT or preventing SIRT6 phosphorylation by mutating Ser 338 prevented the degradation of SIRT6 mediated by MDM2, suppressed the proliferation of breast cancer cells in culture, and inhibited the growth of breast tumor xenografts in mice. Overexpressing MDM2 decreased the abundance of SIRT6 in cells, whereas overexpressing an E3 ligase-deficient MDM2 or knocking down endogenous MDM2 increased SIRT6 abundance. Trastuzumab (known as Herceptin) is a drug that targets a specific receptor common in some breast cancers, and knocking down SIRT6 increased the survival of a breast cancer cell exposed to trastuzumab. Overexpression of a nonphosphorylatable SIRT6 mutant increased trastuzumab sensitivity in a resistant breast cancer cell line. Thus, stabilizing SIRT6 may be a clinical strategy for overcoming trastuzumab resistance in breast cancer patients.
INTRODUCTION
Sirtuins are a family of nicotinamide adenine dinucleotide-dependent deacetylases that are involved in regulating stress resistance, metabolism, and organismal life span (1) . They are mammalian homologs of the yeast silent information regulator 2 (Sir2), and there are seven sirtuins in mammals (SIRT1 to 7). SIRT6 was first identified as a chromatin-associated factor that suppresses genomic instability (2) . SIRT6 controls cellular senescence by localizing to the telomeres and maintaining the telomere structure by deacetylating histone H3 at Lys 9 (3). SIRT6-deficient mice exhibit severe metabolic abnormalities resulting in a degenerative phenotype that includes lymphopenia, osteopenia, loss of subcutaneous fat, and hypoglycemia that is fatal within 10 days (4-6). SIRT6 has both deacetylase and mono-ADP (adenosine 5′-diphosphate)-ribosyltransferase activities that contribute to its role in aging, inflammation, DNA repair, and metabolism (2, 3, (7) (8) (9) (10) (11) (12) . Loss of SIRT6 expression promotes tumorigenesis of the colon and liver (13, 14) . Human breast cancers frequently exhibit loss of heterozygosity (LOH) at chromosome loci 19p13.3, where SIRT6 is located (15) (16) (17) , suggesting that SIRT6 may function as a tumor suppressor in breast tissue.
There are five phosphorylation sites on SIRT6; the Ser 338 residue is critical for the interaction of SIRT6 with a subset of proteins (18) , but no biological consequences of this phosphorylation have yet been identified. Also, the kinase (or kinases) that might be responsible for phosphorylating SIRT6 is unknown. Lin et al. identified ubiquitin-specific peptidase 10 (USP10) as a deubiquitinase for SIRT6 and found that USP10 antagonizes c-Myc-dependent transcription through SIRT6 stabilization (19) . These studies have begun to shed light on the possible regulation of SIRT6. Here, we investigated the molecular mechanisms that lead to loss of SIRT6 activity or protein abundance in breast cancer and the implications for therapeutic strategies involving trastuzumab (commonly known as Herceptin) in breast cancers.
RESULTS

Activation of AKT1 promotes the degradation of SIRT6
The phenotypes of SIRT6 −/− mice, including accelerated aging, cardiac hypertrophy, and reduced life span, are similar to those associated with increased activation of the insulin-like growth factor (IGF)-AKT pathway (20, 21) . SIRT6 inhibits IGF-AKT signaling by inhibiting gene transcription and phosphorylation of AKT (22, 23) . Because the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway is one of the major oncogenic signaling cascades that result in tumor growth and development (24) (25) (26) , we speculated that IGF-AKT signaling might also regulate SIRT6. To determine whether AKT signaling regulates SIRT6 expression, AKT1 and AKT2 were knocked down by silencing RNA [small interfering RNA (siRNA)] in MCF-7 ( Fig. 1, A and B) and MDA-MB-231 (fig. S1A) human breast cancer cells. Only knockdown of AKT1, but not AKT2, resulted in significant increase in SIRT6 protein abundance. We also observed increased reduction in the endogenous SIRT6 protein abundance with overexpression of constitutively active AKT1 in MDA-MB-231 cells (Fig. 1C) and exogenous SIRT6 abundance in human embryonic kidney (HEK) 293T cells ( fig. S1B ). Overexpression of constitutively active AKT3 did not decrease SIRT6 protein abundance ( fig. S1B ), indicating that AKT1 may be the dominant kinase that regulates SIRT6 abundance. Thus, we focused on AKT1 for further experiments. Adding MK2206, an AKT inhibitor, to cultures increased the abundance of SIRT6 in MCF-7, MDA-MB-231, and two additional breast cancer cell lines, HBL-100 and Hs578T (Fig. 1D and fig. S1C ). Treatment with growth factors, such as epidermal growth factor (EGF) and IGF, activated AKT1 and decreased SIRT6 abundance in a time-dependent manner ( Fig. 1E and  fig. S1D ). Furthermore, only the expression of constitutively active, but not the dominantnegative, kinase-deficient AKT1 decreased the abundance of Flag-tagged SIRT6 in HEK293T cells (Fig. 1F) To determine whether AKT1-mediated SIRT6 suppression was because of changes in protein stability, we measured the halflife of a Flag-tagged SIRT6 in HEK293T cells that overexpressed hemagglutinin (HA)-tagged, constitutively active AKT1. The halflife of SIRT6 was shorter in the presence of active AKT1 than it was in the presence of the vector (Fig. 1H) , prompting us to examine whether this decrease was the result of 26S proteasome-mediated degradation. Pretreating HEK293T cells with the proteasome inhibitor MG-132 or the AKT inhibitor MK2206 rescued AKT1-induced suppression of SIRT6 abundance (Fig. 1I) . Additionally, overexpression of AKT1 enhanced the ubiquitination of SIRT6 in the presence of MG-132, which was inhibited by either MK2206 or wortmannin, a PI3K inhibitor ( fig. S1F ). Together, these results suggest that SIRT6 protein abundance is suppressed in a proteasome-dependent manner, and this is dependent on the kinase activity of AKT1.
AKT1 interacts with and phosphorylates SIRT6 on Ser 338
To explore the mechanism of how AKT1 mediates the suppression of SIRT6, we first characterized the interaction between the two proteins. Both endogenous SIRT6 ( Fig. 2A) and exogenous Flag-tagged SIRT6 ( fig. S2A ) physically associated with AKT1 in an immunoprecipitation assay. In addition, endogenous AKT1 interacted with endogenous SIRT6, as shown by reciprocal immunoprecipitation (Fig. 2B) , and an in vitro kinase assay showed that full-length recombinant SIRT6 could be directly phosphorylated by recombinant, functionally active AKT1 (Fig. 2C) . To further identify the AKT1-mediated phosphorylation sites on SIRT6, we isolated SIRT6 from cells treated with EGF or IGF in the presence of MG-132 and analyzed it by mass spectrometry. Three phosphorylation sites were identified on SIRT6: Ser and Ser 338 ( fig. S2B and Fig. 2E ). To determine which site (or sites) is phosphorylated by AKT1, we mutated each one to an alanine residue and subjected all three mutants to in vitro kinase assays. Of these three mutants, phosphorylation was abolished in S338A (Fig. 2D) , suggesting that AKT1 specifically phosphorylates SIRT6 at this position. A search of the National Center for Biotechnology Information database using the Basic Local Alignment Search Tool (BLAST) revealed that Ser 338 of SIRT6, the mass spectrometry profile for which is shown in Fig. 2E , is highly conserved among mammals (Fig. 2F) . Ser 338 was also identified recently by another independent group (18) . To validate whether this site is phosphorylated in cells, we used a commercially available antibody that recognizes SIRT6 phosphorylated at Ser 338 and, thus, detected Flagtagged wild-type but not the nonphosphorylatable S338A mutant SIRT6 in MDA-MB-231 cells (Fig. 2G) . In serum-starved MDA-MB-231 cells treated with IGF-1 for 1 hour in the presence of the protease inhibitor MG-132 to stabilize protein abundance, we observed an increase in SIRT6 phosphorylation at Ser 338 ( Fig. 2H) . Together, these results support that Ser 338 of SIRT6 is an AKT1 phosphorylation site.
MDM2 is required for AKT1-mediated SIRT6 degradation
MDM2 is the most well-characterized oncogenic E3 ligase in the PI3K-AKT pathway and is phosphorylated and activated by AKT (27, 28) . Because AKT1 suppresses SIRT6 protein abundance by decreasing its stability, we investigated whether MDM2 is involved in this process. First, we found that overexpression of wild-type MDM2 but not the MDM2-D9 mutant, which lacks its E3 ligase domain (29) , reduced endogenous SIRT6 abundance in HEK293T cells (Fig. 3A) . In MCF-7 cells, the abundance of SIRT6 increased when MDM2 was knocked down by siRNA (Fig. 3B ). In addition, when ubiquitin was overexpressed concomitantly with MDM2 in HEK293T cells in the presence of MG-132, we observed a polyubiquitination pattern of SIRT6 (Fig. 3C ), suggesting that SIRT6 may be polyubiquitinated for subsequent proteasome degradation. Immunoprecipitation showed that MDM2 interacted with endogenous SIRT6 in MCF-7 cells (Fig. 3D ) and with exogenous Flag-SIRT6 in HEK293T cells (Fig. 3E ). We then analyzed the half-life of SIRT6 by using the protein synthesis inhibitor cycloheximide. Similar to the observations of SIRT6 abundance in HEK293T cells overexpressing a constitutively active AKT1 in the presence of MG-132 (Fig. 1I ), exogenous SIRT6 abundance decreased by 50% in the presence of MDM2 after 4 hours in cycloheximide, whereas MG-132 prevented the degradation of SIRT6 even after 8 hours (Fig. 3F) . Furthermore, SIRT6 could no longer be suppressed by IGF stimulation when MDM2 is knocked down by siRNA in MCF-7 cells ( Fig. 3G) . These results suggest that MDM2 degrades SIRT6 in a proteasomedependent manner.
Phosphorylation of SIRT6 by AKT1 facilitates MDM2-mediated degradation
To further show that the phosphorylation of SIRT6 by AKT1 alters its stability, we compared the stability of two SIRT6 mutant proteins: SIRT6-S338A, a nonphosphorylatable mutant, and SIRT6-S338D, a phosphorylation-mimic mutant. Under cycloheximide treatment in MCF-7 cells, the abundance of SIRT6-S338D decreased after 2 hours, whereas SIRT6-S338A abundance remained unsubstantially changed for at least up to 8 hours (Fig. 4A) . Consistently, the SIRT6-S338D mutant interacted more strongly with MDM2 in MCF-7 cells than did SIRT6-S338A (Fig. 4B) . These results suggest that AKT1-induced phosphorylation of SIRT6 may recruit MDM2 and ubiquitinate SIRT6 to promote its subsequent degradation. To determine whether this interaction indeed promoted SIRT6 degradation, the SIRT6-S338A or SIRT6-S338D mutant was cotransfected with MDM2 into HEK293T cells. As expected, the abundance of SIRT6-S338D, but not SIRT6-S338A, was decreased in the presence of MDM2 (Fig. 4C) . Compared with wild-type SIRT6, the SIRT6-S338D mutant was heavily ubiquitinated and the SIRT6-S338A mutant was the least ubiquitinated in the presence of MDM2 and MG-132 in MCF-7 cells (Fig. 4D) . Together, these data indicate that MDM2 is the E3 ligase that mediates SIRT6 degradation and that the interaction between MDM2 and SIRT6 is dependent on AKT1-mediated SIRT6 phosphorylation on Ser 338 .
Nonphosphorylatable
SIRT6 inhibits breast cancer tumorigenesis
Because the nonphosphorylatable SIRT6 mutant had enhanced stability and the phosphorylation-mimic mutant had less stability compared to the wild-type SIRT6, we examined the function of SIRT6-WT, SIRT6-S338A, and SIRT6-S338D in cellular proliferation and breast cancer tumorigenesis. Knockdown of endogenous SIRT6 by short hairpin RNA (shRNA) increased the proliferation of MDA-MB-231 cells in culture, as determined by a cell counting assay (Fig. 5A) , and enhanced the growth of MDA-MB-231 xenografts in the mammary fat pads of nude mice (Fig. 5B) . We further examined the function of the phosphorylation of SIRT6 at Ser 338 in cell proliferation and tumorigenesis by expressing wild-type or either mutant SIRT6 in MDA-MB-231 cells. Expression of the nonphosphorylatable SIRT6-S338A mutant suppressed cell proliferation (Fig. 5C ) and colony formation on soft agar (Fig. 5D ) more than did wild-type SIRT6 or the phosphorylation-mimic SIRT6-S338D mutant compared to the vector control. To further test the tumor-suppressive activity of SIRT6 mutants in vivo, we injected MDA-MB-231 cells stably expressing the control vector, wild-type SIRT6, or either mutant SIRT6 into the mammary fat pads of nude mice and monitored tumor development. We found that tumor volume in mice injected with MDA-MB-231 cells stably expressing wild-type SIRT6 was smaller than those injected with cells expressing the control vector. The growth of tumors expressing the SIRT6-S338A mutant was significantly decreased compared with those expressing the control vector or the phosphorylation-mimic SIRT6-S338D mutant (Fig. 5E) .
To further investigate whether the expression of SIRT6 phosphomutants affects the endogenous expression of known SIRT6 target genes that are involved in promoting tumorigenesis, we performed a quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis of MDA-MB-231 cells expressing vector control, SIRT6-WT, SIRT6-S338A, or SIRT6-S338D. We found that the SIRT6-S338A mutant suppressed the mRNA abundance of a panel of target genes more significantly (AKT1, AKT3, IGF-1R, PDK1, MTOR, and LDHA) than others (GSK3B and PFKM), whereas the SIRT6-S338D mutant had no inhibitory effect on the target genes compared to SIRT6-WT ( fig. S3 ). SIRT6-deficient mice exhibit increased phosphorylation of AKT compared with controls and subsequently have severe hypoglycemia because of enhanced basal and insulin-stimulated glucose uptake (5). On the other hand, SIRT6-deficient mouse embryonic fibroblasts (MEFs) showed similar amounts of phosphorylated AKT to wild-type MEFs (14) . Thus, we investigated the phosphorylation of AKT in MDA-MB-231 breast cancer cell line that expressed vector, SIRT6-WT, A-SIRT6, or D-SIRT6. Clones were chosen in such a way that the expression of wild-type and mutant SIRT6 were similar, which would make the phosphorylation of AKT comparable. In our system, although there was a slight decrease in the abundance of phosphorylated AKT in the presence of wild-type SIRT6 as previously reported (5), there was no significant difference between the mutants and the wild-type SIRT6 ( fig. S4) , suggesting that the Ser 338 mutation on SIRT6 might not contribute to SIRT6-mediated suppression of AKT activation.
To determine the correlation between SIRT6 phosphorylation and breast cancer patient survival or disease progression, immunohistochemical staining was performed for total and phosphorylated SIRT6 in biopsy tissues from 126 breast cancer patients. Patients whose tumors had high SIRT6 abundance had better overall survival than those whose tumors had low SIRT6 abundance. However, patients whose tumors had high abundance of phosphorylated SIRT6 had poorer overall survival than those whose tumors had low abundance of phosphorylated SIRT6 (Fig. 5, F and G) . These results suggest that SIRT6 and its phosphorylation status may have the potential to be predictive of breast cancer patient survival.
Loss of SIRT6 results in trastuzumab resistance in breast cancer cells overexpressing HER2
Trastuzumab is a standard treatment for patients with HER2-positive breast cancer. However, intrinsic or acquired resistance to this treatment is observed (30, 31) . Increased or constitutive activation of AKT appears to be a key factor in trastuzumab resistance (32) (33) (34) (35) . Because we found that AKT1 decreased SIRT6 stability through phosphorylation and subsequent proteasomedependent degradation, we speculated that SIRT6 might also play a role in trastuzumab resistance. Indeed, SIRT6 abundance was lower in two trastuzumab-resistant, HER2-positive breast cancer cell lines (BT474-TtzmR and SKBR3-TtzmR) compared with trastuzumab-sensitive parental lines (BT474-P and SKBR3-P) (Fig. 6A) . The abundance of SIRT6 increased after the addition of trastuzumab in BT474-P, but not in BT474-TtzmR, cells (Fig. 6B) . In the BT474-P cells, 24-hour treatment with trastuzumab inhibited the phosphorylation of AKT at Ser 473 , whereas in the BT474-TtzmR cells, there was residual phosphorylation of AKT even after 48 hours of trastuzumab treatment. This persistent activation of AKT appeared to attenuate the increase in SIRT6 protein abundance seen in the parental cells, suggesting that the induction of SIRT6 contributes to the therapeutic effect of trastuzumab.
To further validate the above findings, we knocked down SIRT6 in BT474-P cells and cultured them in trastuzumab for 4 days. Loss of SIRT6 in trastuzumab-sensitive BT474-P cells decreased cell sensitivity to trastuzumab to a similar sensitivity seen in BT474-TtzmR cells as measured by relative metabolic activity in an MTT assay (Fig. 6C) . Expression of the nonphosphorylatable SIRT6-S338A mutant considerably resensitized BT474-TtzmR cells to trastuzumab compared with expression of either wild-type SIRT6 or the phosphorylation-mimic SIRT6-S338D mutant (Fig. 6C) . These data suggest a mechanism by which trastuzumab inhibits breast cancer cell proliferation through the induction of SIRT6 and that loss of SIRT6 mediated by AKT1 and MDM2 contributes to trastuzumab resistance. Data are means ± SE from three independent experiments. *P < 0.0001, Student's t test.
DISCUSSION
Our study suggests a model in which the tumor suppressor SIRT6 is inhibited by oncoprotein AKT1 through phosphorylation and subsequent degradation by the MDM2-dependent ubiquitin proteasome pathway (Fig. 7) . We identified an AKT1 phosphorylation site on SIRT6 (Ser 338 ), the phosphorylation of which increased susceptibility to interaction with and degradation by MDM2, a bona fide E3 ligase mediating SIRT6 degradation. Ronnebaum et al. identified C terminus of Hsc70-interacting protein (CHIP) as an E3 ligase that stabilizes SIRT6 through noncanonical ubiquitination (36) . They observed canonical ubiquitination of SIRT6 even in the absence of CHIP, indicating that other E3 ligases like MDM2 might also ubiquitinate and degrade SIRT6. Also, recently, USP10 was shown to interact with, deubiquitinate, and stabilize SIRT6 in colon cancer cells (19) , indicating that SIRT6 could be destabilized through E3 ligase-mediated ubiquitination. USP10 has been shown to deubiquitinate and stabilize p53, a well-known substrate of MDM2 (37) , suggesting a mechanism whereby SIRT6 is ubiquitinated and destabilized by MDM2, which could be reversed by USP10-mediated deubiquitination.
We showed that the nonphosphorylatable SIRT6-S338A mutant is resistant to MDM2-mediated degradation, is more stable than wild-type SIRT6, and exhibits enhanced suppression of cell proliferation and tumor growth. Together with previously reported studies, our results further strengthen the role of SIRT6 as a tumor suppressor in numerous cancers, and loss of SIRT6 is a critical promoter of cancer cell survival.
In addition to promoting tumorigenesis, increased AKT activation is associated with the development of trastuzumab resistance in breast tumors with increased HER2 expression (30, 31, 38) . Consequently, several alternate treatment modifications and combination therapies have been designed to address this issue, including combining trastuzumab with the SRC inhibitor saracatinib (39) or an AKT inhibitor (40) and, most recently, trastuzumab-DM1, in which a cytotoxic agent mertansine is linked to the monoclonal antibody against HER2 (41) . Because SIRT6 abundance was lower in trastuzumab-resistant cells than in trastuzumabsensitive cells, and manipulating SIRT6 abundance modulates sensitivity, the loss of SIRT6 might be one of the mechanisms that enable acquired resistance to trastuzumab, suggesting that histochemical analysis of SIRT6 might be used as a biomarker to determine drug sensitivity in breast cancer patients undergoing trastuzumab treatment.
MATERIALS AND METHODS
Cell lines
All cell lines used were purchased from the American Type Culture Collection. They included HEK293T, a HEK cell line; MCF-7, a human mammary adenocarcinoma cell line from pleural effusion; MDA-MB-231, a human mammary adenocarcinoma cell line from pleural effusion; Hs578T, a human mammary carcinoma cell line; and HBL-100, a human mammary epithelial carcinoma. The BT474 cell line and its trastuzumab-resistant counterpart (BT474-TtzmR) were gifts from D. Yu at The University of Texas MD Anderson Cancer Center (Houston, TX). All cells were grown on tissue culture dishes in Dulbecco's modified Eagle's medium/F12 (DMEM/F12) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and penicillin and streptomycin (100 U, 100 ng/ml) at 37°C in a humidified atmosphere with 5% CO 2 , unless specified otherwise. Before IGF (50 ng/ml) or EGF (50 ng/ml) treatment, the cells were serum-starved overnight. The concentrations and treatment durations of each chemical were as follows: MK2206 (2 mM, 1 hour), MG-132 (10 mM, 7 to 10 hours), and cycloheximide (1 mg/ml). Stable puromycin-resistant cell lines were maintained in DMEM/F12 medium that contained puromycin (1 mg/ml).
Antibodies
Commercial antibodies against SIRT6 (1:1000), AKT1 (1:1000), AKT2 (1:1000), AKT3 (1:1000), and phospho-AKT Ser 473 (1:1000) were purchased from Cell Signaling Technology; antibody against phosphorylated SIRT6 Ser 338 (1:500) was from Abnova; and antibodies against HA (1:2000) and Flag (1:2000) were from Sigma.
Reagents
The AKT inhibitor MK2206 was purchased from Selleck Chemicals. MG-132, cycloheximide, EGF, and IGF were purchased from Sigma.
Plasmids
DNA plasmids encoding Flag-SIRT6 (plasmid 13817), HA-myr-AKT1 (plasmid 9008), and HA-myr-AKT3 (plasmid 9017) were from Addgene. Wild-type MDM2 and the MDM2 deletion mutant (MDM2-D9) were gifts from J. Chen (H. Lee Moffitt Cancer Center, Tampa, FL). SIRT6-S338A and SIRT6-S338D point mutants were generated using the QuickChange Site-Directed Mutagenesis Kit from Stratagene using the following primers: SIRT6-S338D, 5′-GCGGCCCACCGACCCTGCCCCCCACAG-3′ (forward) and 5′-GTGGGGGGCAGGGTCGGTGGGCCGCTC-3′ (reverse). All lentiviral pLKO.1 expression and shRNA-encoding plasmids were purchased from Sigma. SIRT6 shRNA 1 clone ID: TRCN0000232532: CCGGCTCCCTGGT-CTCCAGCTTAAACTCGAGTTTAAGCTGGAGACCAGGGAGTTTTTG; SIRT6 shRNA 2 clone ID: TRCN0000050473:CCGGTGGAAGAATGTGC-CAAGTGTACTCGAGTACACTTGGCACATTCTTCCATTTTTG. Wild-type MDM2 and MDM2 deletion mutants were gifts from J. Chen (H. Lee Moffitt Cancer Center, Tampa, FL). AKT1, AKT2, and MDM2 siRNAs were purchased from Sigma. . Phosphorylation at this residue increases the interaction between SIRT6 and MDM2 and enhances the degradation of SIRT6 through an MDM2-dependent ubiquitin proteasome pathway, contributing to tumorigenesis and trastuzumab resistance in breast cancer.
Immunoblotting, immunoprecipitation, and ubiquitination assays
Immunoblotting, immunoprecipitation, and ubiquitination assays were performed as previously described (25) , using antibodies against SIRT6, AKT1, AKT2, phosphorylated AKT at Ser 473 (Cell Signaling Technology), tubulin, and actin (Sigma). For glutathione S-transferase (GST) pull-down assays, GST-SIRT6 protein (10 mg) was incubated with 2 mg of MCF-7 cell extract overnight at 4°C. GST-tagged proteins were recovered by incubating the reaction mixture with 20 ml of glutathione Sepharose beads at 4°C overnight. The bead pellet was washed three times in 1× phosphate-buffered saline. The boiled samples were then subjected to 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
In vitro kinase assay
Purified GST-SIRT6 (wild-type or mutant) fragments were incubated with active AKT1 (Millipore) and 50 mM ATP (adenosine 5′-triphosphate) in a kinase buffer containing [ 32 P]ATP (5 mCi) for 30 min at 30°C. The reaction products were resolved via SDS-PAGE, and 32 P-labeled products were detected using autoradiography.
Identification of phosphorylation sites by mass spectrometry analysis
HeLa cell lysates were immunoprecipitated with an antibody against SIRT6 to identify the phosphorylation sites of SIRT6 in cells. In vitro, the phosphorylation site of SIRT6 was identified using an in vitro kinase assay with recombinant, active AKT1 kinase and full-length GST-SIRT6. After protein gel electrophoresis, the bands were excised and subjected to digestion with trypsin. The enriched phosphopeptides were isolated using immobilized metal affinity chromatography and analyzed by micro-liquid chromatography-tandem mass spectrometry using an UltiMate Capillary LC system (LC Packings) coupled to a QSTAR XL quadruple time-of-flight mass spectrometer (Applied Biosystems). The product ion spectra, generated by nanoscale capillary spectrometry, were searched against National Center for Biotechnology Information databases for exact matches using the ProID (Applied Biosystems) and MASCOT search programs. Carbamidomethyl cysteine was set as a fixed modification, and serine, threonine, and tyrosine phosphorylation were set as variable modifications. All phosphopeptides identified were confirmed by manual interpretation of the spectra.
Cell growth, soft agar, and cell viability assays Cell growth was determined by cell counting. Cells (1 × 10 5 ) were plated in triplicate in 12-well plates. They were then trypsinized at the indicated time points and counted. For the soft agar transformation assay, 2.5 × 10 4 cells were seeded in 1 ml of DMEM with 10% FBS and 0.4% agarose and overlaid on 1 ml of DMEM with 10% FBS and 0.8% agarose in each well of a six-well plate. After 2 to 3 weeks, colonies larger than 2 mm in diameter were counted.
Animal studies
MDA-MB-231 cells (2 × 10 6 ) with lentiviral-stable expression of SIRT6-WT, SIRT6-S338A, or SIRT6-S338D and Sh SIRT6 or Sh Luc control cells were injected into the mammary fat pads of nude mice (five per group). Tumor size was measured every 3 days with a caliper, and tumor volume was determined using the formula L × W 2 × 0.52, where L is the longest diameter and W is the shortest diameter. All animal procedures were conducted under regulations of Division of Laboratory Animal Medicine at The University of Texas MD Anderson Cancer Center. Animal protocols (protocol number 06-87-06139) were reviewed and approved by the Institutional Animal Care and Use Committee at The University of Texas MD Anderson Cancer Center.
Breast tumor tissue specimens
One hundred twenty-six formalin-fixed and paraffin-embedded infiltrating breast carcinoma patient samples were obtained from the Department of Pathology, Shanghai East Breast Disease Hospital, People's Republic of China. Breast cancer tissue microarray containing 186 cases was purchased from Pantomics (BRC2281).
Immunohistochemical staining
A modified immunoperoxidase staining was used as described previously (42) for staining with SIRT6 (Novus, NB100-2522), phospho-AKT Ser 473 (Cell Signaling Technology, 3787S), and phospho-SIRT6 (Bioss, bs-5634R-bio).
Statistical analysis
SAS software (version 8.1) was used for the statistical analysis (SAS Institute). A univariate analysis was used to determine the variable distributions. Categorical variables among the groups were compared using the c 2 test or Fisher's exact test if 20% of the expected values were less than 5. Continuous variables were analyzed using Student's t test. A P value <0.05 was considered statistically significant.
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